TRANXENOGEN SIGNS MONOCLONAL ANTIBODY DEVELOPMENT PACTS.TranXenoGen, Inc. ("TranXenoGen") has signed an agreement with KS Biomedix Holdings plc, a UK-based biotechnology company, to conduct feasibility studies for the development of a super high-affinity monoclonal antibody monoclonal antibody, an antibody that is mass produced in the laboratory from a single clone and that recognizes only one antigen. Monoclonal antibodies are typically made by fusing a normally short-lived, antibody-producing B cell (see immunity) to a fast-growing . It has also signed an agreement with a leading US monoclonal antibody technology company to conduct feasibility studies for the development of a monoclonal antibody. It is TranXenoGen's strategy to demonstrate the value of its avian transgenic technology for the high-volume, low-cost manufacture of monoclonal antibody products by entering into development agreements with industry leaders in this field. Consequently, TranXenoGen is launching its first pilot evaluation programs with these leading antibody development companies. Commenting on the agreements, TranXenoGen's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steve Parkinson, said: "This is an important next step for TranXenoGen. We are pleased to have evaluation partners of this calibre working with us. Our US partner is providing us with a monoclonal antibody for a first phase proof of principle project. If successful, these programs could lead to full-scale manufacturing contracts. We have always said the most important application of our technology is to the area of high volume monoclonal antibodies and we are seeking to develop a number of these partnerships. "The development of our first four well characterised biologicals products is well underway, and we are now establishing full scale manufacturing facilities. The next stage is to develop monoclonal antibodies in our avian transgenic system." TranXenoGen, Inc. (symbol: TXN TXN Texas Instruments (stock symbol) TXN Transaction (databases) TXN Tunxi, China (Airport Code) TXN Tarxien (postal locality, Malta) .L) is a publicly listed company on the Alternative Investment Market of the London Stock Exchange London Stock Exchange London marketplace for securities. It was formed in 1773 by a group of stockbrokers who had been doing business informally in local coffeehouses. . The company specializes in the application of second-generation transgenic technology to the production of complex high-volume human therapeutic proteins in the egg albumin egg albumin n. The white of an egg. Also called ovalbumin. fraction of transgenic chicken eggs. KS Biomedix Holdings plc (London, UK) is one of the UK's leading biopharmaceutical companies with a late stage pipeline of drugs for anti-inflammatory disease and a powerful platform technology based on sheep monoclonal antibodies (SMA (1) See SMA connector. (2) (Shared Memory Architecture) See shared video memory. (3) (Software Maintenance Association) A membership organization that began in 1985 and ended in 1996. ). The company currently has two products in clinical trials; CBF-BS2, which has just completed Phase II clinical trials for rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. ; and CB-2431 for osteo-arthritis which has also successfully completed a Phase II clinical trial. Its SMA technology enables the isolation of super-high affinity antibodies and is being targeted at a range of commercial opportunities, such as the treatment of colon cancer colon cancer, cancer of any part of the colon (often called the large intestine). Colon cancer is the second most common cancer diagnosed in the United States. . KS Biomedix was founded in 1990 and began operations in 1992. It listed on the Alternative Investment Market of the London Stock Exchange in 1995 and made a full listing on the London Stock Exchange in 1998. For further information, call 001 508 842 5036. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion